Fu et al. [88] exploited the VA linker to generate new treatments against hepatocellular carcinoma by combining Duocarmycin SA and pyrrolobenzodiazepine (PBD) dimer to antibodies targeting GPC3 on hepatocellular carcinoma cell membrane. Here, GPC3 is linked to hepatocellular carcinoma.